Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function...
Transcript of Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function...
![Page 1: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/1.jpg)
Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: the ASTRRA study
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 2: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/2.jpg)
Background
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 3: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/3.jpg)
Primary objective
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 4: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/4.jpg)
Inclusion and exclusion criteria
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 5: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/5.jpg)
Slide 5
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 6: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/6.jpg)
Sample size and statistics (Initial design)
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 7: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/7.jpg)
Trial progress
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 8: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/8.jpg)
Trial progress (protocol amendments)
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 9: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/9.jpg)
Trial progress
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 10: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/10.jpg)
Patient Characteristics I
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 11: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/11.jpg)
Patient Characteristics II
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 12: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/12.jpg)
Frequency and Pattern of OF recovery <br />:defined as FSH<30mIU/mL or menstruation history (N=1,369)
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 13: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/13.jpg)
Disease free survival (Primary Endpoint)
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 14: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/14.jpg)
Disease free survival (Primary Endpoint)
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 15: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/15.jpg)
Slide 15
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 16: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/16.jpg)
Overall Survival (Secondary Endpoint)
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 17: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/17.jpg)
Conclusion
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 18: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/18.jpg)
Supplementary Results
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 19: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/19.jpg)
Sites of distant metastasis
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 20: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/20.jpg)
Sites of other primary cancer
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 21: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/21.jpg)
Recurrence-free interval
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 22: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/22.jpg)
Breast cancer-free interval
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 23: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/23.jpg)
Disease free survival by randomized groups
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 24: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/24.jpg)
Discussion: SOFT vs. ASTRRA
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 25: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/25.jpg)
Acknowledgement
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 26: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/26.jpg)
Acknowledgement
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting
![Page 27: Presented By Woo Chul Noh at 2018 ASCO Annual Meeting · Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal](https://reader033.fdocuments.in/reader033/viewer/2022060306/5f0979937e708231d42700f3/html5/thumbnails/27.jpg)
Special Thanks to
Presented By Woo Chul Noh at 2018 ASCO Annual Meeting